RNS Number : 7396E
Diurnal Group PLC
10 November 2020
10 November 2020
Diurnal Group plc
("Diurnal" or the "Company")
Notice of Interim Results
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will announce its financial results for the six months ended 31 December 2020 on Tuesday 23 February 2021.
|
For further information, please visit
www.diurnal.co.uk
or contact:
|
|
|
|
|
Diurnal Group plc
|
+44 (0)20 3727 1000
|
|
Martin Whitaker, Chief Executive Officer
|
|
|
Richard Bungay, Chief Financial Officer
|
|
|
|
|
|
Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)
|
+44 (0)20 7886 2500
|
|
Corporate Finance: Freddy Crossley, Emma Earl
|
|
|
Corporate Broking: Rupert Dearden
|
|
|
|
|
|
FTI Consulting (Media and Investor Relations)
|
+44 (0)20 3727 1000
|
|
Simon Conway
|
|
|
Victoria Foster Mitchell
|
|
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
NORKKCBQOBDDODK
|
